Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.

ABSTRACT:

Purpose

New treatments are introduced into standard care based on clinical trial results. However, it is not clear if these benefits are reflected in the broader population. This study analysed the clinical outcomes of patients with metastatic castration-resistant prostate cancer, treated with abiraterone and enzalutamide, within the Scottish National Health Service.

Methods

Retrospective cohort study using record linkage of routinely collected healthcare data (study period: February 2012 to February 2017). Overall survival (OS) was analysed using Kaplan-Meier methods and Cox Proportional Hazard models; a subgroup analysis comprised potentially trial-eligible patients.

Results

Overall, 271 patients were included and 73.8% died during the study period. Median OS was po

SUBMITTER: Baillie K 

PROVIDER: S-EPMC8246935 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature